Major Shareholding Notification • Mar 1, 2024
Major Shareholding Notification
Open in ViewerOpens in native device viewer
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response ... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
(Print or Type Responses)
| 1. Name and Address of Reporting Person Drapé Eric |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner |
|---|---|---|
| (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
3. Date of Earliest Transaction (Month/Day/Year) 02/28/2024 |
Officer (give title below) Other (specify below) Executive VP Global Operations |
| (Street) Tel Aviv, L3 6944020 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |
| 1.Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired | 5. Amount of Securities Beneficially | 7. Nature | |||
|---|---|---|---|---|---|---|---|---|---|
| (Instr. 3) | Date | Execution Date, if Code | (A) or Disposed of (D) | Owned Following Reported | Ownership of Indirect | ||||
| (Month/Day/Year) any | (Instr. 8) | (Instr. 3, 4 and 5) | Transaction(s) | Form: | Beneficial | ||||
| (Month/Day/Year) | (Instr. 3 and 4) | Direct (D) Ownership | |||||||
| (A) | or Indirect (Instr. 4) | ||||||||
| Or | |||||||||
| Code | Amount | (D) | Price | (Instr. 4) | |||||
| 'Ordinary Shares (1) | 02/28/2024 | M | 19,515 | A | (2) | 19,516 | D |
| Ordinary Shares (1) 02/28/2024 |
1 | 9.701 | ||
|---|---|---|---|---|
| ----------------------------------- | -- | --- | ------- | -- |
! " # \$ % " & ' ( ) " * + , : ; < = 1 2 , ) - 1 + ! ? @ A B C ? E @ B N O D @ H B D B @ I J E F @ B @ C ? E @ B B E F @ B I J E L B @ M H B G @ K E B C L B @ M G @ N D @ N E F @ |
& ' |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| - 1 P C E E R G |
) " - + / , ' & " 0 1 % ' - 2 3 " 0 4 1 & 5 " 6 9 & 6 ) - 1 3 2 ) ' 6 - 1 + 3 6 ( " & ) ' ! " - + , F O Q @ I J E Q A D @ I J S @ B @ F @ L B @ M F B S B C @ @ I J S @ B ? I J E Q A @ |
4 ' + ! 7 8 9 6 " 0 & ' ) " - > ? @ A N O B F @ K E B B C T A U D @ E F @ E F @ G @ G @ N O B F @ B @ A P F O Q B C |
C P F O Q B C D @ W S E F @ X B O C V C E A D @ W E F @ Z E @ G E @ |
P @ F B C G E @ V C E A W S G @ |
||||||
| Y @ E \ ] 2 ! 6 ) ' 3 4 ^ " - 2 3 6 " _ H B [ L T @ |
N | X B A W U Y S B @ B ? E @ B G G @ G @ |
||||||||
| ` a ? O Q S @ Q N O E S B @ b a I E @ E F @ S @ E B @ U @ U @ B E D @ A O B C |
E |
B C W E F @ A S @ B @ B B @ B S @ |
C @ c F O Y B F |
E H B O S @ B H O O @ E |
D A F |
k U@F-BCYSB-@UK-B@ Reminder: Report on a separate line for each class of securities beneficially owned directly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.